Noxopharm Ltd
Research Noxopharm Ltd (NOX) on Bullrun: market cap AUD 28.88M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNOX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 28.88M
- Financial periodFY2024
- Net income-AUD 3.58M
- Free cash flow-AUD 684.31K
Valuation Snapshot
latest market cap is AUD 28.88M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | n/a | -AUD 3.58M | -AUD 684.31K | n/a | -0.01 | AUD 2.32M | n/a | AUD 5.50M |
| FY2023 | n/a | -AUD 15.06M | -AUD 10.95M | n/a | -0.05 | AUD 3.01M | n/a | AUD 9.07M |
| FY2022 | n/a | -AUD 18.67M | -AUD 13.73M | n/a | -0.06 | AUD 14.01M | AUD 160.62K | AUD 24.12M |
| FY2021 | n/a | -AUD 9.35M | -AUD 8.85M | n/a | -0.04 | AUD 26.80M | AUD 349.31K | AUD 40.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 28.88M | n/a | n/a | n/a |
About Noxopharm Ltd
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Noxopharm Ltd's market cap?
Noxopharm Ltd's market capitalization is AUD 28.88M.
What does Noxopharm Ltd do?
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions.